The DNA Sequencing Facility was approved and funded by the NCI Core Grant in 1994. The Facility received """"""""excellent"""""""" merit at that time. Dr. Haig Kazazian, Chair of Genetics, has served as Facility Director since the inception of this Shared Resource. Dr. Kazazian is a well-known human molecular geneticist who had directed the Genetic Resources Core at Johns Hopkins for five years prior to coming to Penn. The Technical Director of the Facility is Dr. Tapan Ganguly. Dr. Ganguly has over 10 years of experience in cell and molecular biology, and was associated with the genetic Diagnostic Laboratory in Penn's Department of Genetics for three years before assuming this position. During the current project period, the DNA Sequencing Facility has become fully operationalized and well accepted as a major research service to Cancer Center investigators . Usage has grown consistently, with an increase of 14% from 1997 to 1998 alone. New equipment has been purchased in order to meet increasing demand. Additionally, the core has relocated to larger space in order to accommodate its increasing needs. Lastly, automated plasmid purification has been added to the core's service offerings. 53% of total usage is by Cancer Center members, while 34% is by Cancer Center members with peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016520-26S1
Application #
6456213
Study Section
Project Start
2000-12-01
Project End
2001-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
26
Fiscal Year
2001
Total Cost
$228,564
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications